Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Net Income towards Common Stockholders (2016 - 2022)

Historic Net Income towards Common Stockholders for Aptevo Therapeutics (APVO) over the last 8 years, with Q4 2022 value amounting to $521000.0.

  • Aptevo Therapeutics' Net Income towards Common Stockholders rose 6030.77% to $521000.0 in Q4 2022 from the same period last year, while for Sep 2023 it was $521000.0, marking a year-over-year decrease of 3623.01%. This contributed to the annual value of -$18.6 million for FY2023, which is 194106.61% down from last year.
  • As of Q4 2022, Aptevo Therapeutics' Net Income towards Common Stockholders stood at $521000.0, which was up 6030.77% from $165000.0 recorded in Q3 2022.
  • Aptevo Therapeutics' 5-year Net Income towards Common Stockholders high stood at $5.2 million for Q3 2019, and its period low was -$12.9 million during Q2 2019.
  • Over the past 5 years, Aptevo Therapeutics' median Net Income towards Common Stockholders value was $140500.0 (recorded in 2021), while the average stood at -$1.2 million.
  • The largest annual percentage gain for Aptevo Therapeutics' Net Income towards Common Stockholders in the last 5 years was 1313076.92% (2019), contrasted with its biggest fall of 11733636.36% (2019).
  • Aptevo Therapeutics' Net Income towards Common Stockholders (Quarter) stood at $39000.0 in 2018, then soared by 4666.67% to $1.9 million in 2019, then crashed by 93.65% to $118000.0 in 2020, then skyrocketed by 175.42% to $325000.0 in 2021, then skyrocketed by 60.31% to $521000.0 in 2022.
  • Its Net Income towards Common Stockholders stands at $521000.0 for Q4 2022, versus $165000.0 for Q3 2022 and $149000.0 for Q2 2022.